ACHN—Apparently, shortening treatment from 12 to 8 weeks isn’t as compelling a benefit to prescribing docs as most investors thought (#msg-110523630). Moreover, it remains to be seen whether ACH-3422 can simply be substituted for Sovaldi without lowering the SVR12 rate.
Market Data 
Markets 
AI
